> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Moderna Says Two 25-Microgram Doses Met Immune Endpoint in Children Under 6 as Omicron Limits Infection Protection
- URL: https://www.theamericanquorum.com/taq-historical-2022-03-26-healthcare/
- Published: 2022-03-27T03:59:00.000Z
- Updated: 2022-03-27T03:59:00.000Z
- Description: Moderna reported positive immune-response data for two 25-microgram COVID-19 doses in children under 6, while Omicron-era efficacy against infection remained modest.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 11:02

Moderna said this week that its two-dose COVID-19 vaccine regimen for children from 6 months through 5 years met the primary immune-response goals of its KidCOVE trial, giving the company a path toward seeking U.S. authorization for the youngest children who remain ineligible for vaccination.

The company’s [March 23 interim results](https://www.newswire.com/news/moderna-announces-its-covid-19-vaccine-phase-2-3-study-in-children-6-months-to?ref=theamericanquorum.com) covered roughly 6,900 children and used two 25-microgram doses given 28 days apart, one-quarter of the dose used in the company’s original adult primary series. Moderna said antibody responses in both pediatric age groups met prespecified statistical criteria when compared with young adults, while vaccine efficacy against symptomatic infection during the Omicron period was substantially lower than the protection seen against earlier variants.

The company estimated efficacy of about 43.7% among children 6 months to 23 months and 37.5% among those ages 2 through 5\. Those figures reflect a period when Omicron was circulating widely and evading infection-blocking immunity across age groups. [STAT reported](https://www.statnews.com/2022/03/23/moderna-to-ask-fda-to-authorize-covid-19-vaccine-in-children-6-months-to-6-years/?ref=theamericanquorum.com) that Moderna planned to submit the data to the Food and Drug Administration and seek emergency authorization in the coming weeks.

## Immune response, not infection prevention, drives the primary endpoint

For young children, the central regulatory question is whether the lower dose generates an immune response comparable to a regimen already shown to work in adults. The trial was designed around immunobridging, a method that compares antibody levels in the new age group with those in an older group for whom clinical efficacy has already been established. That approach can reduce the need for a pediatric trial to accumulate a large number of severe outcomes before regulators can assess the product.

Moderna said the geometric mean antibody titers and seroresponse rates in both pediatric cohorts met the study’s noninferiority criteria. The company also reported no severe COVID-19 cases, hospitalizations or deaths in the trial at the time of the interim analysis, and no cases of myocarditis or pericarditis. [CBS News](https://www.cbsnews.com/news/moderna-covid-vaccine-kids-children-under-6/?ref=theamericanquorum.com) reported that fevers occurred more often after vaccination than in the placebo group but were generally within expectations for pediatric vaccines.

The distinction between immune response and protection against any symptomatic infection is important. Omicron has reduced the ability of existing vaccines to prevent mild infection even as vaccination continues to protect strongly against severe disease in older groups. An [Associated Press report](https://www.inquirer.com/health/coronavirus/moderna-covid-19-vaccine-children-safe-20220323.html?ref=theamericanquorum.com) on the data noted that the company viewed the observed efficacy as consistent with adult performance during the Omicron wave.

## The youngest children have faced rising hospitalization pressure

The authorization question arrives after a winter surge that put unusually heavy pressure on children under 5\. A [CDC analysis](https://www.cdc.gov/mmwr/volumes/71/wr/mm7111e2.htm?ref=theamericanquorum.com) of COVID-19-associated hospitalizations found that the weekly hospitalization rate among children ages 0 through 4 during the Omicron-predominant period reached about five times the peak rate seen during Delta. The agency found that infants younger than 6 months accounted for 44% of hospitalizations in that age group and that nearly two-thirds of hospitalized children had no underlying medical condition.

Those findings do not mean most infected young children become seriously ill; severe disease remains uncommon on a population basis. But they show why regulators and pediatricians are watching vaccine data closely. A large pool of unvaccinated children exposed to a highly transmissible variant can generate substantial numbers of emergency visits and hospitalizations even when individual risk is low.

CDC’s [March surveillance summary](https://stacks.cdc.gov/view/cdc/115431?ref=theamericanquorum.com) reinforced the same concern, documenting the sharp Omicron-era rise in hospitalization rates among children too young to be vaccinated. Earlier in the winter, CDC officials had also discussed pediatric hospitalization trends in a [January 7 briefing](https://archive.cdc.gov/www%5Fcdc%5Fgov/media/releases/2022/t0107-covid-update.html?ref=theamericanquorum.com), emphasizing vaccination of eligible family members and other protective measures around children who could not yet receive a vaccine themselves.

## A regulatory path still has several steps

Moderna’s announcement is not an authorization. The FDA must receive and evaluate the full submission, including manufacturing information, safety data and the detailed immunogenicity analysis. The agency can then decide whether the known and potential benefits of the vaccine outweigh the known and potential risks for the proposed age group under the emergency-use standard.

If the FDA authorizes the vaccine, the Centers for Disease Control and Prevention would still need to consider recommendations for clinical use. That process typically includes a public review by the Advisory Committee on Immunization Practices, which weighs epidemiology, vaccine performance, safety, implementation and the balance of benefits and risks.

The timing is particularly sensitive because parents of young children have already watched the pediatric authorization process change. Pfizer and BioNTech initially sought consideration of a two-dose regimen for children under 5, but federal review was delayed while additional data on a third dose are gathered. Moderna’s two-dose submission could therefore become the next major test of whether immunobridging data are sufficient to open vaccination to this age group.

## Omicron changes what efficacy numbers mean

The reported infection-efficacy percentages will likely draw attention because they are far below the roughly 90% or greater figures associated with the first generation of COVID-19 vaccine trials in 2020\. But cross-era comparisons can be misleading. The virus circulating now is different, population immunity is different, and the trial endpoint is occurring in an environment where Omicron has repeatedly produced breakthrough infections in vaccinated adults.

For regulators, the more consequential questions will include the strength and consistency of the immune response, the durability of protection, the frequency of adverse events and the likely protection against medically significant disease. Moderna said it continues to collect data and will follow participants after the primary analysis.

The company’s results move the youngest children one step closer to a possible vaccine option, but they also illustrate the changed pandemic landscape. A pediatric vaccine may not prevent most mild Omicron infections. Its value will instead be judged by whether a smaller dose can safely produce meaningful immune protection and reduce the risk that infection progresses to the outcomes parents and clinicians most want to avoid.